If you are not happy with the results below please do another search
Wednesday, Sanofi released data from a Phase II study showing its investigational anti-CD40L antibody frexalimab met the trial’s primary endpoint and significantly lowered disease activity in patients with relapsing multiple sclerosis.
Healthcare company Abbott Laboratories (ABT.N) on Tuesday sued one of its former scientists, accusing him in U.S. court of “secretly downloading” sensitive corporate files containing competitive information about nutrition products.
The FDA has placed a clinical hold on PepGen‘s Phase I trial of its neuromuscular candidate, which had been planned for the first half of the year. The Boston biopharma’s stock dropped around 18% post-market Tuesday after the announcement.
Top-line results from a Phase IIa study showed that Glyscend Therapeutics’ lead candidate GLY-200 demonstrated promising safety and efficacy in patients with Type 2 diabetes, the company announced Wednesday.
Efforts are under way by the FDA to hasten the progress of gene therapies for severe conditions to the market—but reimbursement of these expensive medicines is still at the heart of the challenge.
Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.
Illumina Inc. CEO Francis deSouza survived a challenge to his board seat from activist investor Carl Icahn last week by securing more than twice the shareholder votes than the number his challenger received, the company said in a filing on Tuesday.
Akebia Therapeutics scored a long-awaited win Tuesday when it announced the FDA has granted a path forward for vadadustat in anemia associated with chronic kidney disease in dialysis-dependent patients, which will not require the company to submit new data.
The United States on Tuesday imposed sanctions on 17 people and entities based in China and Mexico who it accused of enabling production of counterfeit fentanyl-laced pills, as the Biden administration seeks to stem imports of the deadly drug.
The FDA has approved Lexicon Pharmaceuticals’ sotagliflozin, now to be marketed as Inpefa, as a once-daily oral medication to cut the risk of cardiovascular death and heart failure admissions and visits in adult patients with underlying heart failure, the company announced Friday.